Moderna announced that it will no longer pursue new late‑stage vaccine trials, a decision that will pause several advanced‑stage candidates and shift the company’s development focus toward oncology and rare‑disease programs.
The halt follows growing opposition to immunizations from U.S. officials, regulatory delays, and a perceived lack of access to the U.S. market. CEO Stéphane Bancel said the company cannot expect a return on investment for phase‑three studies when market entry is uncertain, citing regulatory hurdles and limited U.S. backing as key headwinds.
The pause affects a portfolio of candidates that had reached phase III or late‑stage testing, including a next‑generation influenza vaccine and an RSV vaccine candidate that had shown promising early‑phase results. These programs were expected to contribute to the company’s revenue mix in the coming years.
Financially, the decision is projected to reduce future revenue opportunities, but it aligns with Moderna’s broader strategy to achieve cash break‑even by 2028 through cost reductions and a stronger oncology pipeline. The company’s guidance for 2026 now emphasizes a 10% sales growth driven by its personalized melanoma vaccine partnership with Merck, while operating expenses are expected to decline as the company scales its oncology and rare‑disease initiatives.
The market has reacted positively to the announcement, buoyed by the strong five‑year data from the melanoma vaccine and the company’s improved financial outlook. Investors view the pivot as a move toward higher‑margin, high‑growth segments, offsetting the short‑term revenue drag from the halted vaccine programs.
"We are refocusing our resources on areas where we can deliver the greatest impact and return to shareholders," Bancel said. He added that the company remains committed to its mRNA platform and will continue to explore vaccine opportunities that align with regulatory and market realities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.